Loading…

Medical Research Finder

meRfi® Microbiome - The Digital Gut Microbiome Reference (incl. AI Chat)
Prebiotics, Probiotics, FMT / Manipulators of the Intestinal Microbiota

AuthorsReferences (Sources)

FOLFOX + Nivolumab & Gastroesophageal junction adenocarcinoma (GEJ)

Welcome to meRfi Microbiome!

Please register to continue your trial period!

meRfi Microbiome provides you with up-to-date, evidence-based insights on the gut microbiota and related health topics.

Access our ever-expanding digital library and get personalized answers through our interactive AI chat platform.

Start your free trial and transform your understanding of the gut microbiota today!

FOLFOX + Nivolumab & Gastroesophageal junction adenocarcinoma (GEJ) has received approvals from both the FDA and EMA. These approvals are for the use of nivolumab alongside chemotherapy that includes fluoropyrimidine and platinum compounds. This encompasses treatments like FOLFOX for advanced cases of [gastric cancer](brai…

First-Line Nivolumab Plus Chemotherapy for Advanced Gastric, Gastroesophageal Junction, and Esophageal Adenocarcinoma: 3-Year Follow-Up of the Phase III CheckMate 649 Trial
Janjigian et al. 2024 J Clin Oncol 42(17): 2012-2020
First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): a randomised, open-label, phase 3 trial
Janjigian et al. 2021a The Lancet 398: 27-40
Nivolumab plus chemotherapy or ipilimumab in gastro-oesophageal cancer
Shitara et al. 2022 Nature 603: 942

7/1/2026